Auris Sees A Window To Treat Profound Hearing Loss Despite Phase III Failure

The HEALOS trial testing AM-111 in sudden deafness did not meet the primary efficacy endpoint, but a subpopulation of patients with the worst hearing loss did show a statistically significant benefit.